Liposomal Ruthenium Drug Data for Cisplatin-Resistant Osteosarcoma Models

A 2026 study by Dzohara Murillo investigates a novel ruthenium-based metallodrug, Ru3, and its liposomal encapsulation as an alternative to cisplatin for treating osteosarcoma. The dataset includes TIF and PDF files totaling 5.9 MB, documenting in vitro and in vivo experiments on cisplatin-resistant and parental osteosarcoma models. Findings show liposomal Ru3 exhibited stronger cytotoxicity than cisplatin and was better tolerated in mouse xenograft models.

Use Cases

• Compare drug cytotoxicity between novel ruthenium compounds and cisplatin based on in vitro assay results.
• Evaluate nanomedicine delivery efficacy using liposomal encapsulation data from the description.
• Assess therapeutic outcomes in drug-resistant cancer models based on in vivo xenograft experiment results.
• Investigate cancer stem cell targeting using data from tumorsphere assays mentioned in the study.

Strengths

• Dataset is 5.9 MB, containing specific experimental data in TIF and PDF formats.
• Explicitly compares a novel ruthenium compound (Ru3) to cisplatin across multiple osteosarcoma models.
• Includes results from both 2D cell cultures and 3D spheroid models, as mentioned in the description.
• Provides in vivo data from mouse xenograft experiments with cisplatin-resistant tumors.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect the specific experimental bias inherent to the figshare platform and the single study.

Provenance

Source

figshare

Collection Method

Experimental research data from in vitro and in vivo studies.

Freshness

Last updated 2026-05-12 05:40:04; freshness should be verified.